An alternative form of melarsoprol in sleeping sickness

Trends in Parasitology

Volumn 28, Issue 8, 2012, Pages 307-310

  Kennedy, Peter G E ^a  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Central nervous system (CNS); Complexed melarsoprol; Human African trypanosomiasis (HAT); Sleeping sickness

Indexed keywords

ANTICONVULSIVE AGENT; ANTIPROTOZOAL AGENT; CYCLODEXTRIN DERIVATIVE; EFLORNITHINE; FEXINIDAZOLE; MELARSOPROL; MELARSOPROL CYCLODEXTRIN; NIFURTIMOX; NITROIMIDAZOLE; SCYX 7158; STEROID; TAVABOROLE; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG SOLUBILITY; ENCEPHALITIS; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; INFUSION PUMPS; MELARSOPROL; MICE; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE; TRYPANOSOMIASIS, AFRICAN;

TRYPANOSOMA BRUCEI RHODESIENSE;

EID: 84863843203     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2012.05.003     Document Type: Review

References (17)

1. Kennedy P.G.E. Human African trypanosomiasis of the CNS: current issues and challenges. J. Clin. Invest. 2004, 113:496-504.
2. Kennedy P.G.E. The continuing problem of human African trypanosomiasis (sleeping sickness) in sub-Saharan Africa. Ann. Neurol. 2008, 64:116-126.
3. Simarro P.P., et al. The human African trypanosomiasis control and surveillance programme of the World Health Organisation 2000-2009: the way forward. PLoS Negl. Trop. Dis. 2011, 5:e1007.
4. Odiit M., et al. Quantifying the level of under-detection of Trypanosome brucei rhodesiense sleeping sickness cases. Trop. Med. Int. Health 2005, 10:840-849.
5. Barrett M.P. Potential new drugs for human African trypanosomiasis: some progress at last. Curr. Opin. Infect. Dis. 2010, 23:603-608.
6. The Fatal Sleep 2007, Luath Press. P.G.E. Kennedy (Ed.).
7. World Health Organisation Control and surveillance of African trypanosomiasis. WHO Tech. Rep. Ser. 1998, 881:1-113.
8. Kennedy P.G.E. Diagnostic and neuropathogenesis issues in human African trypanosomiasis. Int. J. Parasitol. 2006, 365:505-512.
9. Lejon V., et al. Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis. J. Infect. Dis. 2003, 187:1475-1483.
10. Schmid C., et al. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J. Infect. Dis. 2005, 191:1922-1931.
11. Priotto G., et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomized, phase III, non-inferiority trial. Lancet 2009, 374:56-64.
12. Vincent I.M., et al. A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS Pathog. 2010, 6:e1001204.
13. Torreele E., et al. Fexinidazole - a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl. Trop. Dis. 2010, 4:e923.
14. Barrett M.P., et al. Development of novel drugs for human African trypanosomiasis. Future Microbiol. 2011, 6:677-691.
15. Jacobs R.T., et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl. Trop. Dis. 2011, 5:e1151.
16. Rodgers J., et al. Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis. PLoS Negl. Trop. Dis. 2011, 5:e1308.
17. Gibaud S., et al. Melarsoprol-cyclodextrins inclusion complexes. Int. J. Pharm. 2005, 306:107-121.